Master Aztreonam (Azactam) with Picmonic for Nursing RN

Aztreonam has a limited or narrow antimicrobial spectrum, as it is only effective against gram-negative aerobic bacteria.

Aztreonam is a bactericidal antibiotic. These drugs inhibit cell wall synthesis by binding to specific proteins and weakening the bacterial cell wall. The disruption of the cell wall's integrity causes bacterial cell lysis and death.

Aztreonam is not a broad-spectrum antibiotic and is only effective against gram-negative infections.

Due to its limited spectrum, aztreonam is not effective against infections caused by gram-positive or anaerobic bacteria.

Aztreonam is used in cystic fibrosis to treat respiratory infections caused by gram-negative bacteria, particularly Pseudomonas aeruginosa.

Although aztreonam is typically administered IV or IM, it can also be administered via a nebulizer. This route of administration is commonly used to treat respiratory infections in patients with cystic fibrosis.

Aztreonam causes mild to moderate digestive disturbances. Symptoms can include nausea, vomiting, diarrhea, and abdominal pain. These symptoms are generally self-limiting and not severe, but they can impact patient comfort and adherence to the medication.

Patients may experience pain at the injection site. Thrombophlebitis, or inflammation of the vein due to a blood clot (thrombus), may also occur.

Aztreonam is structurally different from penicillin and is generally safe for use in individuals with a penicillin allergy without the risk of cross-sensitivity. It is important to note that some patients allergic to penicillins may exhibit hypersensitivity reactions to aztreonam. Obtain a thorough history prior to initiating therapy.

Combining aztreonam with an aminoglycoside antibiotic, such as gentamicin or tobramycin, has been shown to have a synergistic effect against certain microorganisms, especially Pseudomonas aeruginosa.